Track Acceleron Pharma's current cash ($590M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2021), XLRN shows a current cash of $590M. That compares with $880M in the prior-year period — down 33.1% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, XLRN's current cash is now $590M (was $880M) — a 33.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Acceleron Pharma is outperforming or lagging.
Tracking XLRN's current cash over time shows whether Acceleron Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $590M That compares with $880M in the prior-year period — down 33.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this current cash page, Stockcircle has Acceleron Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $590M) with ownership activity and broader fundamentals.
Acceleron Pharma's current cash is $590M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.